FORTEO Drug Patent Profile

When do Forteo patents expire, and what generic alternatives are available?

Forteo is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in FORTEO is teriparatide. There are four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the teriparatide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Forteo

A generic version of FORTEO was approved as teriparatide by APOTEX on November 16^th, 2023.

Summary for FORTEO

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FORTEO

Paragraph IV (Patent) Challenges for FORTEO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FORTEO	Injection	teriparatide	250 mcg/mL, 2.4 mL prefilled Pen	021318	1	2015-07-27

US Patents and Regulatory Information for FORTEO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318-002	Jun 25, 2008	AP	RX	Yes	Yes
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318-001	Nov 26, 2002		DISCN	No	No

International Patents for FORTEO

See the table below for patents covering FORTEO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	018526	COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED
Austria	260113
Australia	1717799
Australia	759726
Brazil	9813463
Canada	2314313	SOLUTIONS DE TERIPARATIDE STABILISEES (STABILIZED TERIPARATIDE SOLUTIONS)
China	1198644

Last updated: February 3, 2026

What is FORTEO?

FORTEO is the brand name for teriparatide, a recombinant form of parathyroid hormone (PTH 1-34). It is used to treat osteoporosis by stimulating bone formation. Approved by the FDA in 2002, its indications include postmenopausal women with osteoporosis at high fracture risk, men with osteoporosis, and individuals with glucocorticoid-induced osteoporosis. The drug is administered via daily subcutaneous injections, with a typical course limited to 24 months due to safety concerns.

What are the core market fundamentals?

Market Size and Growth

The osteoporosis therapeutics market was valued at approximately $11.8 billion in 2022 and is projected to reach $17.4 billion by 2030, growing at a CAGR of around 4.4% (source: Grand View Research). The key drivers include an aging population, rising osteoporosis prevalence, and increased awareness of fracture risks.

Key Competitors

FORTEO competes primarily with bisphosphonates (e.g., alendronate, risedronate), denosumab (Prolia), and anabolic agents like abaloparatide (Tymlos) and romosozumab (Evenity). While bisphosphonates dominate the market, anabolic agents like FORTEO target patients with severe osteoporosis or those intolerant to bisphosphonates.

Usage Patterns

• Dosage duration is limited; typically, 24 months.
• Post-treatment, patients often switch to antiresorptive agents to sustain bone density benefits.
• Reimbursement policies cover both brand-name FORTEO and biosimilars in some regions, influencing market dynamics.

What are the drug’s economic fundamentals?

Pricing and Revenue

• List price per 28-day pen is approximately $3,000–$3,500 in the U.S.
• The total annual market revenue from FORTEO is estimated between $250–$350 million, considering patient volume and differentiated payer coverage.
• Pricing strategies face pressure from biosimilar competition and payers demanding discounts.

Patent and Regulatory Status

• Original patent protections expired or will expire by 2029, opening space for generics or biosimilars.
• The drug remains under patent protection in key territories, with specific patents covering formulation and delivery methods.

Cost Structure

• Manufacturing costs are driven by recombinant protein synthesis, requiring advanced bioprocessing.
• R&D investments focus on new formulations and delivery devices to extend patent life or improve adherence.

What are the key investment risks?

Competitive Landscape

• Biosimilars entering the market could erode pricing power.
• New anabolic therapies and novel agents are under clinical development, which could replace FORTEO in treatment algorithms.

Safety and Usage Limitations

• Risk of osteosarcoma observed in rodent studies limits prescribed duration.
• Administration requirements (daily injections) impact patient adherence.

Regulatory and Reimbursement Risks

• Changes in reimbursement policies or stricter insurance coverage can reduce patient access.
• Pending patent expirations may lead to biosimilar market entries, increasing price competition.

What is the outlook for the pipeline and future growth?

• Research is ongoing for longer-acting formulations and alternative delivery methods.
• Combination therapies, integrating FORTEO with other osteoporosis drugs, are under investigation to enhance efficacy.

What are the strategic considerations for stakeholders?

• Pharmaceutical companies face a balance of patent expirations against opportunities in biosimilars.
• Investment in R&D for next-generation anabolic therapies offers growth potential.
• Navigating reimbursement frameworks remains essential to market share maintenance.

Key Takeaways

• FORTEO is a niche anabolic osteoporosis treatment with limited duration use.
• The market faces a shift towards biosimilars, which pressure pricing.
• Therapeutic competition, safety profile, and formulation innovations influence long-term market prospects.
• Focus on R&D, pipeline development, and strategic patent management is crucial for companies in this space.

FAQs

1. How long can patients use FORTEO?

   • Typically, up to 24 months due to safety concerns regarding osteosarcoma risk demonstrated in animal studies.

2. Who are the primary competitors?

   • Bisphosphonates, denosumab, abaloparatide, and romosozumab.

3. When will biosimilars enter the FORTEO market?

   • Patent expirations are expected around 2029, opening market for biosimilars.

4. What is the risk associated with FORTEO?

   • Limited duration of use, high cost, and competition from new anabolic agents.

5. Are there ongoing efforts to improve delivery?

   • Yes, research includes longer-acting formulations and alternative administration devices.

---

References

[1] Grand View Research, "Osteoporosis Drugs Market Size, Share & Trends Analysis," 2022

[2] U.S. Food & Drug Administration, "Forteo (teriparatide) prescribing information," 2002

[3] EvaluatePharma, "Pharmaceutical Market Data," 2023

[4] IMS Health, "Biopharmaceutical Trends," 2022

[5] PatentVue, "Biologic and biosimilar patent landscape for teriparatide," 2023